What does the best real-world evidence for AI monitoring actually look like?
The most rigorous real-world validation of an AI monitoring tool in the papers provided comes from a 2023 clinical study of an AI-based MRI analysis system for multiple sclerosis [1]. This is the closest analogy to workplace AI monitoring because it involves automated, continuous assessment of a person's status over time. The study used 397 MRI scan pairs from routine clinical practice across multiple centers — not a controlled lab experiment — and compared the AI tool's performance against both standard radiology reports and a consensus expert ground truth. The AI detected new or enlarging brain lesions with 93.3% sensitivity, while standard radiology reports only caught 58.3% — a 35 percentage point gap. This means the AI missed only about 7 out of 100 cases of disease activity, whereas human reports missed about 42 out of 100. The AI also matched a specialized clinical trial imaging lab on measuring brain volume loss (mean -0.32% vs -0.36%), a key biomarker of neurodegeneration. This study shows that when AI monitoring is designed with clear, quantifiable endpoints and tested against a gold-standard comparator in real-world conditions, it can produce highly reliable evidence.
How does workplace AI monitoring evidence compare — and why is it weaker?
Workplace AI monitoring evidence is far less mature. A 2025 survey of 207 employees in Finnish and international companies found that AI adoption did not directly impact employee wellbeing; instead, it only indirectly influenced wellbeing through improvements in task optimization and safety [3]. This is a much softer endpoint than the clinical study's lesion detection rate, and the sample size is small. More tellingly, a 2025 living systematic review protocol — a plan to continuously update evidence as it emerges — explicitly states that the field is still too new to draw firm conclusions about how AI systems affect worker safety, health, and wellbeing [4]. The protocol notes that researchers are still defining what types of AI systems are being used and how their design impacts workers. This stands in stark contrast to the clinical study, which had a validated outcome measure (lesion detection) and a clear comparator (standard radiology reports). The gap between the two is not just about different settings — it's about the entire maturity of the evidence base. Clinical AI monitoring has reached the point of large-scale, multi-center validation; workplace AI monitoring is still at the stage of small surveys and protocol development.
What separates reliable from unreliable real-world evidence for AI monitoring?
The papers reveal three key factors that determine whether real-world evidence for AI monitoring is trustworthy. First, the outcome must be objectively measurable. The clinical AI study used a consensus ground truth — multiple experts agreeing on what was actually happening in each MRI scan — and the AI's performance was measured against that standard [1]. Workplace studies, by contrast, often rely on self-reported wellbeing or perceptions, which are subjective and harder to verify [3]. Second, the study design matters enormously. A 2022 perspective from the FDA clarifies that 'real-world evidence' is not a single thing — it can come from randomized trials that use real-world data, or from observational studies, and the reliability depends on the specifics of the design [2]. The clinical study was essentially a diagnostic accuracy study with a clear reference standard; the workplace survey was a cross-sectional survey with no control group. Third, the evidence must be replicable across settings. The clinical study used data from multiple centers and still found consistent results; the workplace survey was limited to companies headquartered in Finland, raising questions about generalizability. Until workplace AI monitoring studies adopt objective, independently verifiable outcomes and larger, more diverse samples, their real-world evidence will remain less reliable than what has already been achieved in clinical AI monitoring.
About These Sources
This answer is built on 5 peer-reviewed studies — published from 2022 to 2025, 2 from 2024 or later, 5 in Q1 journals, collectively cited 269 times — selected as the most relevant from 5 studies that passed quality screening, drawn from 39 papers retrieved from a database of over 500 million.
Sources used in this answer
A real-world clinical validation for AI-based MRI monitoring in multiple sclerosis
In a multi-center clinical validation using 397 real-world MRI scan pairs, an AI-based monitoring tool detected multiple sclerosis disease activity with 93.3% sensitivity versus 58.3% for standard radiology reports, and matched a specialized trial imaging lab on brain volume loss measurements (mean -0.32% vs -0.36%).
Real-World Evidence — Where Are We Now?
This FDA perspective clarifies that 'real-world evidence' is not a single category — it can come from randomized trials using real-world data or from observational studies, and reliability depends on study design specifics, not just the label.
AI and employee wellbeing in the workplace: An empirical study
A 2025 survey of 207 employees found that AI adoption does not directly impact employee wellbeing but indirectly influences it through improvements in task optimization and safety, highlighting the indirect and subjective nature of workplace AI monitoring outcomes.
Artificial intelligence in the workplace: a living systematic review protocol on worker safety, health, and well-being implications
This living systematic review protocol (2025) states the field of AI's impact on worker safety, health, and wellbeing is still too new for firm conclusions, with researchers still defining what AI systems are used and how they affect workers.
Workplace Social Capital: Redefining and Measuring the Construct
This 2022 study developed and validated a Workplace Social Capital Inventory (WoSCi) across 733 employees in 158 work groups, showing that social capital is a measurable workplace resource distinct from individual psychological capital, relevant to understanding how monitoring might affect trust and collaboration.